

In the Claims:

Please amend claims 1, 13-17 and 20-21 as indicated.

1. (Currently amended) A method of treating a condition in a mammal, comprising administering to said mammal a pharmaceutically effective amount of ~~20kDa hGH-V SEQ ID NO:7~~, or a polypeptide that is substantially identical to ~~20kDa hGH-V SEQ ID NO:7~~
2. (Original) The method of claim 1, wherein said condition is adult-onset growth hormone deficiency.
3. (Original) The method of claim 1, wherein said condition is childhood-onset growth hormone deficiency.
4. (Original) The method of claim 1, wherein said condition is cystic fibrosis.
5. (Original) The method of claim 1, wherein said condition is osteoporosis.
6. (Original) The method of claim 1, wherein said condition is skeletal dysplasia.
7. (Original) The method of claim 1, wherein said condition is chronic kidney failure.
8. (Original) The method of claim 1, wherein said condition is depression.
9. (Original) The method of claim 1, wherein said condition is memory loss.
10. (Original) The method of claim 1, wherein said condition is a catabolic state.
11. (Original) The method of claim 1, wherein said condition is anorexia.

12. (Original) The method of claim 1, wherein said condition is hypertension.
13. (Currently amended) A pharmaceutical composition comprising a ~~20kDa hGH-V SEQ ID NO:7~~ and a pharmaceutically acceptable excipient.
14. (Currently amended) ~~A The pharmaceutical composition of Claim 13, further comprising a 20kDa hGH-V, a pharmaceutically acceptable excipient and a binder.~~
15. (Currently amended) ~~A The pharmaceutical composition of claim 14, further comprising a 20kDa hGH-V, a pharmaceutically acceptable excipient and a capsule.~~
16. (Currently amended) A method for treating a patient in need of growth hormone therapy, comprising administering to said patient a pharmaceutically effective amount of 20kDa hGH-V SEQ ID NO:7.
17. (Currently amended) The method of claim 16, wherein step of administering includes administering an expression vector capable of producing ~~20kDa hGH-V said SEQ ID NO:7~~.
18. (Original) The method of claim 17, wherein said expression vector is in a host cell.
19. (Original) The method of claim 17, wherein said expression vector is in a cell of the patient.
20. (Currently amended) A method for reducing lactogenic effects associated with growth hormone therapy, comprising administering to a mammal in need of growth hormone therapy, a said composition comprising a pharmaceutically effective amount of 20kDa hGH-V SEQ ID NO:7 or a polypeptide that is substantially identical to 20kDa hGH-V SEQ ID NO:7.
21. (Currently amended) The method of claim 20, wherein said step of administering

includes administering to said mammal, a cell having a replicable vector therein capable of producing 20kDa hGH-~~V~~ said SEQ ID NO:7.